ODC-IL2 / Trutino Biosci - LARVOL DELTA

Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Trutino Biosciences Inc.

New P1 trial • Oncology • Solid Tumor

Novel protease activatable linker with tumor targeting motifs enhances the retention of cytokine prodrug and active cytokine at disease site and demonstrates improved efficacy in preclinical model (SITC 2021) - "The ODC-IL2 panel was tested in vivo as single agent in the subcutaneous syngeneic B16F10 melanoma model...Superior anti-tumor efficacy was observed for all stroma targeting pro-cytokines with near complete tumor growth inhibition achieved with the dual targeting site construct. Conclusions We have demonstrated that the On Demand Cytokine platform can generate protease-activatable cytokine prodrugs with enhanced tumor retention and on-target activity, to ultimately deliver safer and more effective immunotherapies."

Preclinical • Melanoma • Oncology • Solid Tumor • IFNG • IL2

[VIRTUAL] On demand cytokine, a novel cytokine prodrug, demonstrates robust single agent efficacy without systemic toxicity in syngeneic tumor models. (AACR 2021) - "Recombinant IL-2 (aldesleukin) is a potent T cell proliferation and differentiation factor and is an approved immunotherapy for advanced melanoma and renal cell carcinoma. Single agent efficacy of ODC-IL2 in subcutaneous syngeneic tumor models with diverse TME composition is shown. In conclusion, we have demonstrated proof of concept of the On Demand Cytokine platform and its potential to deliver safe and effective immunotherapies."

Preclinical • Genito-urinary Cancer • Melanoma • Oncology • Renal Cell Carcinoma • Solid Tumor • CD8 • IL2 • IL2RA